Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16601427rdf:typepubmed:Citationlld:pubmed
pubmed-article:16601427lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C0546837lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C1519429lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:16601427lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:16601427pubmed:issue2lld:pubmed
pubmed-article:16601427pubmed:dateCreated2006-4-7lld:pubmed
pubmed-article:16601427pubmed:abstractTextMetastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months. Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma.lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:languageenglld:pubmed
pubmed-article:16601427pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:citationSubsetIMlld:pubmed
pubmed-article:16601427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601427pubmed:statusMEDLINElld:pubmed
pubmed-article:16601427pubmed:monthAprlld:pubmed
pubmed-article:16601427pubmed:issn1537-453Xlld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:AbbruzzeseJam...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:DakhilShaker...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:GandaraDavid...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:AtkinsJames...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:BlankeCharles...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:WilliamsonSte...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:YostKathleen...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:McCoySheryl...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:ParadeloJorge...lld:pubmed
pubmed-article:16601427pubmed:authorpubmed-author:Southwest...lld:pubmed
pubmed-article:16601427pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16601427pubmed:volume29lld:pubmed
pubmed-article:16601427pubmed:ownerNLMlld:pubmed
pubmed-article:16601427pubmed:authorsCompleteYlld:pubmed
pubmed-article:16601427pubmed:pagination116-22lld:pubmed
pubmed-article:16601427pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:meshHeadingpubmed-meshheading:16601427...lld:pubmed
pubmed-article:16601427pubmed:year2006lld:pubmed
pubmed-article:16601427pubmed:articleTitlePhase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.lld:pubmed
pubmed-article:16601427pubmed:affiliationUniversity of Kansas Medical Center, Kansas City, KS, USA. swilliam@kumc.edulld:pubmed
pubmed-article:16601427pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16601427pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16601427pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:16601427pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed